Dr. James Krainson

Pulmonary Medicine
Office
12620 SW 120th St Ste 117, 
Miami, FL 
Office
12620 SW 120th St Ste 117, 
Miami, FL 

Overview

James Krainson is a Pulmonary Medicine provider in Miami, Florida. His top areas of expertise are Obstructive Sleep Apnea, Asbestosis, Severe Acute Respiratory Syndrome (SARS), and Narcolepsy.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Office
12620 SW 120th St Ste 117, Miami, FL 33186

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 8 Less Clinical Trials

5 Total Publications

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Journal: JAMA
Published: January 14, 2022
Similar Doctors
Expertise in
18
conditions
Dr. Farzad Rahaghi
Pulmonary Medicine
Expertise in
18
conditions
Dr. Farzad Rahaghi
Pulmonary Medicine

Office

2950 Cleveland Clinic Blvd Fl 3, 
Weston, FL 
 (27.9 miles away)
954-659-5450
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farzad Rahaghi is a Pulmonary Medicine provider in Weston, Florida. Dr. Rahaghi is highly rated in 18 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency (AATD), Interstitial Lung Disease, Lung Transplant, and Vertebroplasty.

Expertise in
28
conditions
Dr. Elio Donna
Pulmonary Medicine
Expertise in
28
conditions
Dr. Elio Donna
Pulmonary Medicine

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (14.7 miles away)
305-243-6387
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elio Donna is a Pulmonary Medicine provider in Miami, Florida. Dr. Donna is highly rated in 28 conditions, according to our data. His top areas of expertise are Lymphofollicular Hyperplasia, Lung Metastases, Lung Cancer, Acute Interstitial Pneumonia, and Advanced Bronchoscopy.

Expertise in
21
conditions
Dr. Michael Hernandez
Pulmonary Medicine
Expertise in
21
conditions
Dr. Michael Hernandez
Pulmonary Medicine

Office

7000 SW 97th Ave Ste 120, 
Miami, FL 
 (4.1 miles away)
786-299-5419
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Hernandez is a Pulmonary Medicine provider in Miami, Florida. Dr. Hernandez is highly rated in 21 conditions, according to our data. His top areas of expertise are Atypical Pneumonia, Hospital-Acquired Pneumonia, Lung Metastases, Pneumonia, and Advanced Bronchoscopy.

Frequently Asked Questions about Dr. James Krainson

How do I make an appointment with Dr. James Krainson?

You can book an appointment with Dr. James Krainson by calling their office at 305-255-0777. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Krainson a top-rated expert for Obstructive Sleep Apnea?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Krainson is classified as an Experienced expert for Obstructive Sleep Apnea, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Krainson specialize in?

While Dr. James Krainson is a Pulmonary Medicine, they have specific expertise in Obstructive Sleep Apnea, Asbestosis, and Severe Acute Respiratory Syndrome (SARS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. James Krainson participate in research or clinical trials?

Yes. Dr. James Krainson has published 5 articles and abstracts on conditions like Obstructive Sleep Apnea. You can view a list of Dr. James Krainson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James Krainson accept my insurance?

Dr. James Krainson accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 305-255-0777 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krainson's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile